Weekly Intraperitoneal Chemotherapy for Ovarian Cancer
Author Information
Author(s): Yu Zang, Li Zi Ting, Tang Jie, Huang Xiao, Mo Cai Shu
Primary Institution: Fudan University Cancer Hospital
Hypothesis
Can weekly intraperitoneal chemotherapy improve survival in patients with advanced epithelial ovarian cancer after surgery?
Conclusion
Weekly postoperative intraperitoneal therapy is practical and associated with longer survival in patients with advanced ovarian cancer.
Supporting Evidence
- Patients with residual disease > 1 cm had a median survival of 21.6 months with IP therapy compared to 18.8 months without.
- In patients with residual disease ≤ 1 cm, median survival was 46.8 months with IP therapy versus 37.6 months without.
- Complications were observed in 29.5% of patients, but no grade 4 toxicities occurred.
Takeaway
This study found that giving chemotherapy directly into the belly every week after surgery can help people with advanced ovarian cancer live longer.
Methodology
Retrospective review of 426 patients treated between 1990 and 1999, comparing those who received weekly intraperitoneal therapy with those who did not.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective and lacks a randomized controlled trial design.
Participant Demographics
Median age was 51 years, with 331 patients having stage III disease and 78 patients having stage IV disease.
Statistical Information
P-Value
0.02
Confidence Interval
0.56–0.90
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website